



Evolving Our Understanding of PrEP for Cisgender Women

Friday, April 5, 2024 9am ET – 10:30am ET

Welcome.

Thank you for joining us.







HIV prevention research – a new forum for advocacy on the latest

avac.org/project/choice-agenda

Today's playlist

Better Be Good to Me **Tina Turner**

Woman **Doja Cat**

A Natural Woman Aretha Franklin

BODYGUARD Beyoncé

More Than You Know **Axwell Ingrosso**





DJ Jimberly





Evolving Our Understanding of PrEP for Cisgender Women

Today's speakers: Dr. Jeanne Marrazzo, NIAID Joyce Ng'ang'a, WACI Health

> Moderator: Raniyah Copeland, Equity & Impact Solutions

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

Jeanne Marrazzo, MD MPH¹; Li Tao, PhD²; Marissa Becker, PhD³; Ashley A. Leech, PhD, MS⁴; Allan W. Taylor, MD⁵, MPH; Faith Ussery, MPH⁵; Michael Kiragu, MBBS⁶; Sushena Reza-Paul, MBBS, MPH, PhD⁷; Janet; Myers, PhD, MPH⁸; Linda-Gail Bekker, PhD⁹; Juan Yang, PhD²; Christoph Carter, MD, PhD²; Melanie de Boer, PhD²; Moupali Das, MD²; Jared M. Baeten, MD²; Connie Celum, MD, MPH¹⁰

¹National Institute of Allergy and Infectious Diseases, Rockville, Maryland; ²Gilead Sciences, Inc., Foster City, CA, USA ³University of Manitoba, Winnipeg, Manitoba, Canada; ; ⁴Vanderbilt University School of Medicine, Nashville, TN, USA; ⁵Centers for Disease Control and Prevention, Atlanta, GA, USA, ⁶LVCT Health, Nairobi, Kenya; Centre for Global Public Health, ⁷Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada and Ashodaya Samithi, Mysuru, India; ⁸Center for AIDS Prevention Studies, University of California, San Francisco; ⁹The Desmond Tutu HIV Centre, Cape Town, South Africa; ¹⁰University of Washington, Seattle



National Institute of Allergy and Infectious Diseases **National Institutes of Health**

Updated August 30, 2022


Background

- Emtricitabine and tenofovir disoproxil fumarate (F/TDF) for PrEP was approved for adults in 2012 and extended to adolescents in 2018^{1,2}
- Real-world effectiveness and adherence with F/TDF for PrEP in cisgender women remain concerns
- We pooled data from 11 F/TDF demonstration projects in 6 countries conducted over eight years (11/2012–12/2020) with 6,296 participants to better understand the overall efficacy of F/TDF in cisgender women in real-world settings
- We explored adherence in a subset of 2,954 women with available objective and subjective data and used innovative methods to describe longitudinal patterns of adherence

1. Food and Drug Administration (FDA): FDA approves first drug for reducing the risk of sexually acquired HIV infection. Washington, DC, 2012. 2. National Institutes of Health. Item of Interest: FDA Approves PrEP Therapy for Adolescents at Risk for HIV. https://www.nichd.nih.gov/newsroom/releases/051618-PrEP. Published May 16, 2018.




Eleven Demonstration Projects of F/TDF for PrEP in Cisgender Women (N = 6296)



1. Leech AIDS Patient Care STDS 2020; 2. Koester IAPAC 2019; 3. Reza-Paul Glob Public Health 2020; 4. Jana Int J STD AIDS 2021;32:638-47; 5. Masyuko Sex Health 2018; 6. Haberer Lancet HIV 2021 (MPYA); 7. Haberer J Acquir Immune Defic Syndr 2022; 8. Heffron Gates Open Res 2018; 9. Baeten PLOS Medicine 2016; 10Henderson FL, et al. IAS 2015; https://www.natap.org/2015/IAS/IAS 92.htm; 11. Celum J Int AIDS Soc. 2022; 12.Celum J Int AIDS Soc 2020.



Methods: Incidence and Adherence



Between November 2012 and December 2020, 6,296 cisgender women initiated F/TDF for PrEP*

We calculated overall efficacy
(HIV incidence per 100 PY)
by Poisson regression

We evaluated adherence in a subset (n=2955) who had either objective or self-reported data


*Study medication (F/TDF) was provided by Gilead.



National Institute of Allergy and Infectious Diseases

Methods: Adherence Metrics

- Objective adherence measured by TFV-DP in dried blood spots (reflecting adherence over the past 12 weeks) or plasma TFV (reflecting adherence over the past 2-7 days)
- Subjective adherence measures included electronic pill cap-monitoring (ECM), pill counts (PC), self-report (SR) or study-reported adherence scale (SS)
- All measures categorized by corresponding estimated tablets per week





National Institute of *5 Allergy and Infectious Diseases Ng


*51 participants had only TFV plasma level data; those with TFV ≥40 ng/mL were assigned to the 4–6 Tablets group, and those with TFV <40 ng/mL to the <2 Tablets group DBS, dried blood spot Brooks K. Anderson, P. Clin Pharmacol Ther. 2018:104:1056-9

Methods: Longitudinal Patterns of Adherence by Groupbased Trajectory

- Adherence measures assessed at an individual visit reflect cross-sectional adherence at that single time point
- In this analysis, we used group-based trajectory modeling to identify patterns of adherence over 96 weeks
- Linear, quadratic, or cubic models employed to allow data to cluster into 2-6 groups based on ordinal adherence metrics
- Using Bayes and Akaike information criterion (BIC, AIC), the final models were selected and groups defined



Baseline Characteristics



	n (%)
Age at PrEP initiation	
Mean age	25 years (7 [SD])
<25 years	1629 (26)
Primary education or less	1675 (27)
Married	3256 (51)
≥1 Children	2775 (44)
Sexually transmitted infections	781 (12)
BMI ≥30 kg/m²	776 (12)
Commercial sex worker	1294 (21)

N = 6296 n(%)


HIV Incidence (N = 6296)

		HIV Diagnoses / r	HIV Incidence per 100 PY (95% CI)	
Characteristic		32 / 6296	⊢	0.72 (0.51-1.01)
Age at Enrollment	<25	26 / 3832		1.33 (0.90-1.95)
	≥25	6 / 2464		0.24 (0.11-0.53)
Marital Status	Married	20 / 3256		1.15 (0.74-1.78)
	Single	10 / 1791		0.66 (0.35-1.22)
Education	≤Primary	4 / 1675		0.22 (0.08-0.59)
	≥Secondary	11 / 1899		0.58 (0.32-1.05)
Parity	Nulliparous	14 / 1816	• • • • • • • • • • • • • • • • • • •	1.68 (0.99-2.83)
	≥1 Child	7 / 1506		0.71 (0.34-1.49)
	•		D 1 2 3	



- National Institute of Allergy and Infectious Diseases
- Characteristics associated with higher incidence are consistent with those previously described

Cross-sectional Objective and Subjective Adherence by Visit (n = 2922)



Objective (DBS), n=147


Subjective (ECM, PC, SR, SS), n=2775

- By both measures, overall adherence declined over time
- Higher adherence reported with subjective vs objective measures



DBS, dried blood spot; ECM, electronic pill cap-monitoring; PC, pill-counts; SR, self-report; SS, study-reported adherence scale.


Longitudinal Patterns of Adherence By Group-based Trajectory



- Group-based trajectory modeling shows four groups with distinct patterns of adherence
- Three groups had stable adherence over time, regardless of model used
- One group had dynamic adherence over time initially high then declined



HIV Incidence Rates Among Women with Available Adherence Data (n = 2954)



 Even with low incidence overall, higher patterns of adherence were directly associated with lower risk of HIV acquisition



Limitations

- Pooled analysis of heterogeneous demonstration projects
- Differential follow-up (higher adherence associated with higher retention)
- Objective adherence data was available for limited number of women
- Group-based trajectory methodology depends on sample size & duration of follow-up



Conclusions

- This pooled analysis of >6000 cisgender women is the largest assessment of effectiveness and adherence of F/TDF in diverse, global, real-world settings
- Effectiveness of F/TDF was similar in cisgender women who demonstrated consistently high (>4 tablets/week) or high (7 tablets/week) adherence

– Comparable to the adherence-efficacy relationship for cisgender MSM

- Broader context surrounding individuals' HIV prevention needs should be integrated into decisions about PrEP use and that cisgender women need not be restricted to a rigid daily regimen.
 - Similar to the adherence forgiveness that has been reported in cisgender MSM.
- However, over half of all participants did not use F/TDF consistently, highlighting the urgent need for additional prevention options such as long- acting modalities



Acknowledgements

We extend our thanks to all who participated in the original Demonstration Projects who made these additional analyses possible.

This analysis was funded by Gilead. The Bill & Melinda Gates Foundation, California HIV Research Program, CDC, NIH, and USAID funded the original Demonstration Projects.

Disclosures: M. Becker: none; L.-G. Bekker: honoraria for advisory roles for Merck PTY LTD, Gilead, ViiV, Jansen; C. Celum: served as scientific advisor, expert witness and received study drug from Gilead; M. Kiragu: none; A. A. Leech: none; A. Taylor, F. Ussery: received study drug from Gilead (TDF2 OLE study); J. Yang, M. de Boer, C. Carter, M. Das, J. Baeten, L. Tao: employees and stockholders of Gilead. Editing and production assistance were provided by BioScience Communications, New York, NY, funded by Gilead.



National Institute of Allergy and nfectious Diseases

HIV Incidence Rate by Country

	Total N	HIV Diagnoses	Incidence Rate (95% CI)
Botswana	102	0	
India	1325	0	
Kenya	2886	15	0.70 (0.42, 1.17)
South Africa	1751	12	2.67 (1.52, 4.72)
USA	49	0	
Uganda	183	5	2.91 (1.21, 7.00)





The more we know: evolving our understanding of PrEP for Cisgender women

5th April 2024,

Joyce Nganga, WACI Health AWPCAB Member





AWPCAB Members: 11 Women, 7 Countries Kenya, South Africa, Uganda, Tanzania, Zambia, Zimbabwe, Malawi



How we are organized and What we do

Geography: Eastern & Southern Africa

Choice Agenda: Introduction of options

Age:

Intergenerational intentional AGYW

Focus:

Policy change Access and roll out Financing for choice **Engagements:** National, Regional, and Global Levels


The HIV Prevention Choice Manifesto For Women and Girls In Africa

Introductions

The HIV Presention Choice Mandhelis is a collection of volces of African women, and girls in all their diversity, formations and HIV presention advocation across Southern and Eastern Africa who are unlead to caliting for continued publicat and financial toggoot for HV prevention choice.

Biomedical HW prevention is at a foldoric turning point, tust only if incurring and fundams feed evidence toward dements that programs must emphasize choice - not individual products - and that research, and development of new prevention splicing continues.

For the first time in the holitary of the HNV apatemis, it is possible to tould a prevention program conterned answed choice – othering on array of optimes, including or all PCE. The Digitalities vaginal ring, injectable Catestagram and conducting, with straightforward language docut rises and Genetika, as well as vagger/Twe counseling its sciencing optimes that means an individual's needs.





Geat

A future free of HIV for our daughters and wamen in Africa Our nesses to patiet by an HV provedue spend that

- Defairs girls, seaters and communities and exclusives. The right to choose what works for her and them.
- Prioritizes the principle of CHOICE, offering a spectrum of proversion appoints, and adaptable propriaries for women and pirts as they surgists through the different diages and circumstances of their stees.
- Faculation, itselfs is antipite/files abdecard gifts and young women in Africa and of African descent across the world.
- Positions telecare worker and pills all the center and forebrand - not only for research, for also for access to products that are shown to be safe and affective.
- It conceptualized by the contenuity and a responsive to contenuity needs and provides.
- Epilerent the science and exect-spidemiological evidence to provide viable options to women and pits who are evidenable to HS infections.
- Processing to any other and the second othe second other and the second other and the second other and t

The HIV Prevention Choice Manifesto for women and Girls in Africa

Goal: A future free of HIV for our daughters and women in Africa

Call to Action

Center People & Communities

 Prioritize key and marginalized populations and scale interventions Ensure that R&D and delivery are informed by communities in alignment with the <u>Good</u>
<u>Participatory Practice Guidelines</u> –communities must inform the ongoing and future pipeline from the onset, design, and formulation, as well as the introduction of proven interventions.

Choice Is Key

□ Ensure **massive scale-up and increased access** to all safe and effective HIV prevention methods

Ensure women have control over their health and their bodies and access to the full range of safe and effective options so that they can choose what works best for them at different times of their lives

Call to Action

Programs That Deliver

□ **Integrate HIV prevention** into existing information and service packages such as family planning, cervical cancer prevention, antenatal care, and postnatal care to ensure easy access and availability of prevention methods

Finance choice


□Strategize, staff, budget, and procure for choice-based HIV prevention **The Future**

□ **The current options are good, but not sufficient** – prioritise R&D of additional systemic and non-systemic options

Adopt a Human Rights based approach to choice

□Address stigma, discrimination, and criminalization

Launched: September 8th,2023



Reflections on the paper: PrEP use in cisgender women

Prevention Vs treatment

- We have unacceptably high rates of new HIV infections among cisgender women, particularly in regions where rates of PrEP use remain low. We are out of track to meeting global goals of ending AIDS by 2030.
- Many cisgender women may perceive themselves to be at low risk of acquiring HIV, especially if they are in monogamous relationships or do not engage in behaviors traditionally associated with higher risk, such as injection drug use or having multiple sexual partners.
- Purposeful inclusion of cisgender women in PrEP studies and robust data collection to address gender-specific gaps in HIV prevention and treatment
- How we communicate about the studies will have an impact on who will demand the products. Who are we designing the products for?

Reflections: PrEP use in cisgender women

Adherence

- Support PrEP adherence and expand options for HIV prevention among cisgender women.
- Barriers to adherence: low perception of HIV risk, stigma, and poor social support, highlighting the need for tailored adherence support measures. Long-acting PrEP options, such as injectable cabotegravir, offer promise in alleviating adherence challenges.
- Strategies to improve adherence: Tailored counseling and support services, destigmatizing PrEP use, improving access to healthcare, addressing privacy concerns, and providing financial assistance or incentives for medication adherence.
- Address concerns: Pregnancy and Reproductive Concerns, Side Effects, and Concerns about Long-Term Effects: Partner consent

Reflections: PrEP use in cisgender women

Service delivery

- □ Friendly settings for women
- □ Provider attitude determines uptake.
- Communication should be clear and should allow cisgender women make a choice
- Adherence counseling: acknowledge that high, but less-than-perfect adherence still offers significant HIV protection to alleviate anxiety around missed doses and refocus conversations on individual motivations and challenges.